Back

Wild-type transthyretin cardiac amyloidosis: sex differences in prevalence, phenotype, and prognosis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Cardiac amyloidosis (1) Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Assistant Professor Amira Zaroui

University Hospital Henri Mondor, Creteil (France)

9 More presentations in this session

Presentation thumbnail
Discussant - Cardiac amyloidosis (1)
Presentation thumbnail
The role of nutritional status, measured by serum albumin, as a prognostic factor in wild-type transthyretin amyloidosis
Mr S. Decotto (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and follow-up outcomes of patients with wild-type transthyretin amyloidosis: comparison of the pre- and post-bone scintigraphy eras in a Latin American center.
Miss P. Domenech (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Predictors of major adverse cardiovascular events in patients with wild-type transthyretin amyloid cardiomyopathy: insights from a regional hospital experience
Doctor A. Martins (Leiria, PT)
Abstract Slides Video
Presentation thumbnail
Real-world effectiveness of tafamidis in a contemporary, matched cohort of patients with variant and wild-type transthyretin amyloid cardiomyopathy
Doctor M. Maurer (New York, US)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Cardiac amyloidosis (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Sex-based differences in phenotypic expression and prognosis of transthyretin cardiac amyloidosis associated with the Val122Ile variant
thumbnail
Congress Presentation
Unraveling gender differences in hereditary transthyretin amyloidosis: insights from the REACT registry
thumbnail
Congress Presentation
Gender differences in cardiac transthyretin amyloidosis: diagnostic gap in female patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources